Was surprised to hear Dr. Patterson answered on Dr. Drew show recently that CD8 increase with leronlimab treatment was probably just change in moving the cells between compartments. So, less CD8 T-cells homing to lungs and more therefore in plasma. No overall increase in production of CD8 T-cells, just moved around some due to blockage of their homing beacon sensor (CCR5).

The answer didn't really inspire confidence that it would help the lungs to "better clear virally infected cells." Agree that if it keeps T-regs away from infected cells that would be good, as would the repolarization of macrophages to non-inflammatory type.

It's strange that BP answered the question differently just a few days apart on Twitter vs. Dr. Drew.

I thought it interesting in cancer when BP gave another talk (the hour+ long one with Q&A last week at a virtual conference?) that he said it was all about the dosing of CCR5 antagonists, as want to keep the TRegs away from cancer cells, but allow the CD8 killer T-cells in. I think the same is true with virally infected lungs.